Cats, cancer and comparative oncology

Veterinary Sciences

Volumn 2, Issue 3, 2015, Pages 111-126

  Cannon, Claire M ^a,b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Animal models; Comparative oncology; Feline cancer

Indexed keywords

EID: 85002267258     PISSN: None     EISSN: 23067381     Source Type: Journal    
DOI: 10.3390/vetsci2030111     Document Type: Review

References (124)

1. Henson, M.S. O'Brien, T.D. Feline models of type 2 diabetes mellitus. ILAR J. 2006, 47, 234-242
2. Narfstrom, K.; Deckman, K.H.; Menotti-Raymond, M. Cats: A gold mine for ophthalmology. Ann. Rev. Anim. Biosci. 2013, 1, 157-177
3. Gordon, I.; Paoloni, M.; Mazcko, C.; Khanna, C. The Comparative Oncology Trials Consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 2009, 6, e1000161
4. Gordon, I.K.; Khanna, C. Modeling opportunities in comparative oncology for drug development. ILAR J. 2010, 51, 214-220
5. Tamazian, G.; Simonov, S.; Dobrynin, P.; Makunin, A.; Logachev, A.; Komissarov, A.; Schevchenko, A.; Brukhin, V.; Cherkasov, N.; Svitin, A.; et al. Annotated features of domestic cat-Felis catus genome. GigaScience 2014, 3, doi:10.1186/2047-217X-3-13. Available online: http://www.gigasciencejournal.com/content/3/1/13 (accessed on 25 June 2015)
6. Lindblad-Toh, K.; Wade, C.M.; Mikkelsen, T.S.; Karlsson, E.K.; Jaffe, D.B.; Kamal, M.; Clamp, M.; Chang, J.L.; Kulbokas, E.J., 3rd.; Zody, M.C.; et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438, 803-819
7. Butler, L.M.; Bonnett, B.N.; Page, R.L. Withrow and MacEwen's Small Animal Clinical Oncology, 5th ed.; Withrow. S.J., Vail. D.M., Page. R.L., Eds.; Elsevier Saunders: St Louis, MO, USA, 2012; pp. 68-82
8. MacVean, D.W.; Monlux, A.W.; Anderson, P.S., Jr.; Silberg, S.L.; Roszel, J.F. Frequency of canine and feline tumors in a defined population. Vet. Pathol. 1978, 15, 700-715
9. Paoloni, M.; Khanna, C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8, 147-156
10. Bergkvist, G.T.; Argyle, D.J.; Pang, L.Y.; Muirhead, R.; Yool, D.A. Studies on the inhibition of feline EGFR in squamous cell carcinoma: Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors. Cancer Biol. Therapy 2011, 11, 927-937
11. De Maria, R.; Olivero, M.; Iussich, S.; Nakaichi, M.; Murata, T.; Biolatti, B.; Di Renzo, M.F. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005, 65, 907-912
12. Santos, S.; Bastos, E.; Baptista, C.S.; Sá, D.; Caloustian, C.; Guedes-Pinto, H.; Gärtner, F.; Gut, I.G.; Chaves, R. Sequence variants and haplotype analysis of cat ERBB2 gene: A survey on spontaneous cat mammary neoplastic and non-neoplastic lesions. Int. J. Mol. Sci. 2012, 13, 2783-2800
13. Thomas, R. Cytogenomics of Feline Cancers: Advances and Opportunities. Vet. Sci. 2015, in preparation
14. Bartlett, P.C.; Van Buren, J.W.; Neterer, M.; Zhou, C. Disease surveillance and referral bias in the veterinary medical database. Prev. Vet. Med. 2010, 94, 264-271
15. Teclaw, R.; Mendlein, J.; Garbe, P.; Mariolis, P. Characteristics of pet populations and households in the Purdue Comparative Oncology Program catchment area, 1988. J. Amer. Vet. Med. Assoc. 1992, 201, 1725-1729
16. Volk, J.O.; Felsted, K.E.; Thomas, J.G.; Siren, C.W. Executive summary of phase 2 of the Bayer veterinary care usage study. J. Amer. Vet. Med. Assoc. 2011, 239, 1311-1316
17. Volk, J.O.; Felsted, K.E.; Thomas, J.G.; Siren, C.W. Executive summary of the Bayer veterinary care usage study. J. Amer. Vet. Med. Assoc. 2011, 238, 1275-1282
18. American Veterinary Medical Association. U.S. Pet Ownership Statistics. 2012. Available online: https://www.avma.org/KB/Resources/Statistics/Pages/Market-research-statistics-US-pet-ownersh ip.aspx (accessed on19 March 2015)
19. Gruen, M.E.; Jiamachello, K.N.; Thomson, A.; Lascelles, B.D. Clinical trials involving cats: What factors affect owner participation? J. Feline Med. Surg. 2014, 16, 727-735
20. Thamm, D.H.; Grunerud, K.K.; Rose, B.J.; Vail, D.M.; Bailey, S.M. DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: A case-control study. PLoS ONE 2013, 8, e69192
21. Lipinski, M.J.; Froenicke, L.; Baysac, K.C.; Billings, N.C.; Leutenegger, C.M.; Levy, A.M.; Longeri, M.; Niini, T.; Ozpinar, H.; Slater, M.R.; et al. The ascent of cat breeds: Genetic evaluations of breeds and worldwide random-bred populations. Genomics 2008, 91, 12-21
22. Kurushima, J.D.; Lipinski, M.J.; Gandolfi, B.; Froenicke, L.; Grahn, J.C.; Grahn, R.A.; Lyons, L.A. Variation of cats under domestication: Genetic assignment of domestic cats to breeds and worldwide random-bred populations. Anim. Genet. 2013, 44, 311-324
23. Egenvall, A.; Bonnett, B.N.; Haggstrom, J.; Ström Holst, B.; Möller, L.; Nødtvedt, A. Morbidity of insured Swedish cats during 1999-2006 by age, breed, sex, and diagnosis. J. Feline Med. Surg. 2010, 12, 948-959
24. Egenvall, A.; Nødtvedt, A.; Haggstrom, J.; Ström Holst, B.; Möller, L.; Bonnett, B.N. Mortality of life-insured Swedish cats during 1999-2006: Age, breed, sex, and diagnosis. J. Vet. Intern. Med. 2009, 23, 1175-1183
25. Rissetto, K.; Villamil, J.A.; Selting, K.A.; Tyler, J.; Henry, C.J. Recent trends in feline intestinal neoplasia: An epidemiologic study of 1, 129 cases in the veterinary medical database from 1964 to 2004 J. Am. Anim. Hosp. Assoc. 2011, 47, 28-36
26. Ebner, T.; Schänzle, G.; Weber, W.; Sent, U.; Elliott, J. In vitro glucuronidation of the angiotensin II receptor antagonist telmisartan in the cat: A comparison with other species. J. Vet. Pharmacol. Therapeut. 2013, 36, 154-160
27. van Beusekom, C.D.; Fink-Gremmels, J.; Schrickx, J.A. Comparing the glucuronidation capacity of the feline liver with substrate-specific glucuronidation in dogs. J. Vet. Pharmacol. Therapeut. 2014, 37, 18-24
28. Knapp, D.W.; Richardson, R.C.; DeNicola, D.B.; Long, G.G.; Blevins, W.E. Cisplatin toxicity in cats. J. Vet. Intern. Med. 1987, 1, 29-35
29. Saba, C.F.; Schmiedt, C.W.; Freeman, K.G.; Edwards, G.L. Indirect assessment of dihydropyrimidine dehydrogenase activity in cats. Vet. Compar. Oncol. 2013, 11, 265-271
30. Musser, M.L.; Quinn, H.T.; Chretin, J.D. Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats. J. Feline Med. Surg. 2012, 14, 871-875
31. Gustafson, D.L.; Page, R.L. Cancer Chemotherapy. In: Withrow and MacEwen's Small Animal Clinical Oncology, 5th ed, ; Withrow, S.J., Vail, D.M., Page, R.L., Eds.; Elsevier Saunders: St Louis, MO, USA; 2012; pp. 157-179
32. Bertone, E.R.; Snyder, L.A.; Moore, A.S. Environmental and lifestyle risk factors for oral squamous cell carcinoma in domestic cats. J. Vet. Intern. Med. 2003, 17, 557-562
33. Belcher, R.; Hayes, K.; Fedewa, S.; Chen, A.Y. Current treatment of head and neck squamous cell cancer. J. Surg. Oncol. 2014, 110, 551-574
34. Huber, M.A.; Tantiwongkosi, B. Oral and oropharyngeal cancer. Med. Clin. North Amer. 2014, 98, 1299-1321
35. Munday, J.S.; Aberdein, D. Loss of retinoblastoma protein, but not p53, is associated with the presence of papillomaviral DNA in feline viral plaques, Bowenoid in situ carcinomas, and squamous cell carcinomas. Vet. Pathol. 2012, 49, 538-545
36. Munday, J.S.; Fairley, R.A.; Mills, H.; Kiupel, M.; Vaatstra, B.L. Oral Papillomas Associated With Felis catus Papillomavirus Type 1 in 2 Domestic Cats. Vet. Pathol. 2015, doi:10.1177/0300985814565133. Available online: http://vet.sagepub.com/content/early/2015/01/ 02/0300985814565133 (accessed on 26 June 2015)
37. Munday, J.S.; Howe, L.; French, A.; Squires, R.A.; Sugiarto, H. Detection of papillomaviral DNA sequences in a feline oral squamous cell carcinoma. Res. Vet. Sci. 2009, 86, 359-361
38. Munday, J.S.; French, A.F. Felis catus papillomavirus types 1 and 4 are rarely present in neoplastic and inflammatory oral lesions of cats. Res. Vet. Sci. 2015. doi: 10.1016/j.rvsc.2015.03.002. Available online: http://www.sciencedirect.com/science/article/pii/S0034528815000569
39. Farcas, N.; Lommer, M.J.; Kass, P.H.; Verstraete, F.J. Dental radiographic findings in cats with chronic gingivostomatitis (2002-2012). J. Amer. Vet. Med. Assoc. 2014, 244, 339-345
40. Liptak, J.M.; Withrow, S.J. Cancer of the Gastrointestinal Tract. In: Withrow and MacEwen's Small Animal Clinical Oncology, 5th ed, ; Withrow, S.J., Vail, D.M., Page, R.L., Eds.; Elsevier Saunders: St Louis, MO, USA; 2012; pp. 381-431
41. Mognetti, B.; Di Carlo, F.; Berta, G.N. Animal models in oral cancer research. Oral Oncol. 2006, 42, 448-460
42. Ribeiro, F.A.; Noguti, J.; Oshima, C.T.; Ribeiro, D.A. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: A promising approach. Anticancer Res. 2014, 34, 1547-1552
43. Bergkvist, G.T.; Argyle, D.J.; Morrison, L.; MacIntyre, N.; Hayes, A.; Yool, D.A. Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). Vet. Compar. Oncol. 2011, 9, 106-117
44. Looper, J.S.; Malarkey, D.E.; Ruslander, D.; Proulx, D.; Thrall, D.E. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. Vet. Compar. Oncol. 2006, 4, 33-40
45. Sabattini, S.; Marconato, L.; Zoff, A.; Morini, M.; Scarpa, F.; Capitani, O.; Bettini, G. Epidermal growth factor receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. J. Feline Med. Surg. 2010, 12, 760-768
46. Yoshikawa, H.; Ehrhart, E.J.; Charles, J.B.; Thamm, D.H.; Larue, S.M. Immunohistochemical characterization of feline oral squamous cell carcinoma. Amer. J. Vet. Res. 2012, 73, 1801-1806
47. Tannehill-Gregg, S.H.; Levine, A.L.; Rosol, T.J. Feline head and neck squamous cell carcinoma: A natural model for the human disease and development of a mouse model. Vet. Compar. Oncol. 2006, 4, 84-97
48. Snyder, L.A.; Bertone, E.R.; Jakowski, R.M.; Booner, M.S.; Jennings-Ritchie, J.; Moore, A.S. p53 expression and environmental tobacco smoke exposure in feline oral squamous cell carcinoma. Vet. Pathol. 2004, 41, 209-214
49. Faust, R.A.; Gapany, M.; Tristani, P.; Davis, A.; Adams, G.L.; Ahmed, K. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: Association with malignant transformation. Cancer Lett. 1996, 101, 31-35
50. Cannon, C.M.; Trembley, J.H.; Modiano, J.F.; Cespedes Gomez, O.; Kren, B.; Unger, G.; Ahmed, K. CK2 inhibition in feline cancer cell lines using synthetic oligonucleotides. In Proceedings of the American Veterinary Internal Medicine Forum, Seattle, WA, USA, June 2013
51. Wypij, J.M.; Fan, T.M.; Fredrickson, R.L.; Barger, A.M.; de Lorimier, L.P.; Charney, S.C. In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats. J. Vet. Intern. Med. 2008, 22, 158-163
52. Moriyama, M.; Kumagai, S.; Kawashiri, S.; Kojima, K.; Kakihara, K.; Yamamoto, E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol. 1997, 33, 369-374
53. Hayes, A.; Scase, T.; Miller, J.; Murphy, S.; Sparkes, A.; Adams, V. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. J. Compar. Pathol. 2006, 135, 93-99
54. Wakshlag, J.J.; Peters-Kennedy, J.; Bushey, J.J.; Loftus, J.P. 5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats. Amer. J. Vet. Res. 2011, 72, 1369-1377
55. Wang, Z.M.; Liu, J.; Liu, H.B.; Ye, M.; Zhang, Y.F.; Yang, D.S. Abnormal COX2 protein expression may be correlated with poor prognosis in oral cancer: A meta-analysis. BioMed Res. Int. 2014, doi:10.1155/2014/364207. Available online: http://www.hindawi.com/journals/bmri/ 2014/364207/ (accessed on 25 June 2015)
56. Celenk, F.; Bayramoglu, I.; Yilmaz, A.; Menevse, A.; Bayazit, Y. Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma. J. Craniofac. Surg. 2013, 24, 1114-1117
57. Ballegeer, E.A.; Madrill, N.J.; Berger, K.L.; Agnew, D.W.; McNiel, E.A. Evaluation of hypoxia in a feline model of head and neck cancer using 64Cu-ATSM positron emission tomography/computed tomography. BMC Cancer 2013, 13, doi:10.1186/1471-2407-13-218. Available online: http://www.biomedcentral.com/1471-2407/13/218 (accessed on 25 June 2015)
58. Martin, C.K.; Dirksen, W.P.; Shu, S.T.; Werbeck, J.L.; Thudi, N.K.; Yamaguchi, M.; Wolfe, T.D.; Heller, K.N.; Rosol, T.J. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma. Oral Oncol. 2012, 48, 491-499
59. Martin, C.K.; Tannehill-Gregg, S.H.; Wolfe, T.D.; Rosol, T.J. Bone-invasive oral squamous cell carcinoma in cats: Pathology and expression of parathyroid hormone-related protein. Vet. Pathol. 2011, 48, 302-312
60. Martin, C.K.; Dirksen, W.P.; Carlton, M.M.; Lanigan, L.G.; Pillai, S.P.; Werbeck, J.L.; Simmons, J.K.; Hildreth B.E., 3rd.; London, C.A.; Toribio, R.E.; Rosol, T.J. Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma. Vet. Compar. Oncol. 2013, doi:10.1111/vco.12037. Available online: http://onlinelibrary.wiley.com/doi/10.1111/vco.12037/epdf (accessed on 25 June 2015)
61. Martin, C.K.; Werbeck, J.L.; Thudi, N.K.; Lanigan, L.G.; Wolfe, T.D.; Toribio, R.E.; Rosol, T.J. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma. Cancer Res. 2010, 70, 8607-8616
62. Chen, L.F.; Cohen, E.E.; Grandis, J.R. New strategies in head and neck cancer: Understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 2010, 16, 2489-2495
63. Pang, L.Y.; Bergkvist, G.T.; Cervantes-Arias, A.; Yool, D.A.; Muirhead, R.; Argyle, D.J. Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition. Vet. J. 2012, 193, 46-52
64. Battaglia, V.; DeStefano Shields, C.; Murray-Stewart, T.; Casero R.A., Jr. Polyamine catabolism in carcinogenesis: Potential targets for chemotherapy and chemoprevention. Amino Acids 2014, 46, 511-519
65. Chen, Y.; Weeks, R.S.; Burns, M.R.; Boorman, D.W.; Klein-Szanto, A.; O'Brien, T.G. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int. J. Cancer 2006, 118, 2344-2349
66. Skorupski, K.A.; O'Brien, T.G.; Guerrero, T.; Rodrigeuz, C.O.; Burns, M.R. Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma. Vet. Compar. Oncol. 2011, 9, 275-282
67. Trembley, J.H.; Unger, G.M.; Korman, V.L.; Tobolt, D.K.; Kazimierczuk, Z.; Pinna, L.A.; Kren, B.T.; Ahmed, K. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett. 2012, 315, 48-58
68. Unger, G.M.; Kren, B.T.; Korman, V.L.; Kimbrough, T.G.; Vogel, R.I.; Ondrey, F.G.; Trembley, J.H.; Ahmed, K. Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma. Mol. Cancer Ther. 2014, 13, 2018-2029
69. Pierre, F.; Chua, P.C.; O'Brien, S.E.; Siddiqui-Jain, A.; Bourbon, P.; Haddach, M.; Michaux, J.; Nagasawa, J.; Schwaebe, M.K.; Stefan, E.; et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol. Cell. Biochem. 2011, 356, 37-43
70. Marconato, L.; Buchholz, J.; Keller, M.; Bettini, G.; Valenti, P.; Kaser-Hotz, B. Multimodal therapeutic approach and interdisciplinary challenge for the treatment of unresectable head and neck squamous cell carcinoma in six cats: A pilot study. Vet. Compar. Oncol. 2013, 11, 101-112
71. Poirier, V.J.; Kaser-Hotz, B.; Vail, D.M.; Straw, R.C. Efficacy and toxicity of an accelerated hypofractionated radiation therapy protocol in cats with oral squamous cell carcinoma. Vet. Radiol. Ultrasound 2013, 54, 81-88
72. VetCancerTrials.org. Available online: http://www.vetcancertrials.org/studies/analysis-of-vegfrpdgfr-and-c-kit-in-feline-oral-squamous-cell-carcinoma (accessed on 12 May 2015)
73. Hayes, H.M., Jr.; Milne, K.L.; Mandell, C.P. Epidemiological features of feline mammary carcinoma. Vet. Rec. 1981, 108, 476-479
74. Sorenmo, K.U.; Worley, D.R.; Goldschmidt, M.H. Tumors of the Mammary Gland. In Withrow and MacEwen's Small Animal Clinical Oncology, 5th ed.; Withrow, S.J., Vail, D.M., Page, R.L., Eds.; Elsevier Saunders: St Louis, MO, USA; 2012; pp. 538-556
75. Benjamin, S.A.; Lee, A.C.; Saunders, W.J. Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet. Pathol. 1999, 36, 423-436
76. Sorenmo, K.U.; Kristiansen, V.M.; Cofone, M.A.; Shofer, F.S.; Breen, A.M.; Langeland, M.; Mongil, C.M.; Grondahl, A.M.; Teige, J.; Goldschmidt, M.H. Canine mammary gland tumours; A histological continuum from benign to malignant; Clinical and histopathological evidence. Vet. Compar. Oncol. 2009, 7, 162-172
77. Overley, B.; Shofer, F.S.; Goldschmidt, M.H.; Sherer, D.; Sorenmo, K.U. Association between ovarihysterectomy and feline mammary carcinoma. J. Vet. Intern. Med. 2005, 19, 560-563
78. Taylor, M.R. Genetic testing for inherited breast and ovarian cancer syndromes: Important concepts for the primary care physician. Postgraduate Med. J. 2001, 77, 11-15
79. Wiese, D.A.; Thaiwong, T.; Yuzbasiyan-Gurkan, V.; Kiupel, M. Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer 2013, 13, 403
80. Beha, G.; Muscatello, L.V.; Brunetti, B.; Asproni, P.; Millanta, F.; Poli, A.; Benazzi, C.; Sarli, G. Molecular phenotype of primary mammary tumours and distant metastases in female dogs and cats. J. Compar. Pathol. 2014, 150, 194-197
81. Brunetti, B.; Asproni, P.; Beha, G.; Muscatello, L.V.; Millanta, F.; Benazzi, C.; Sarli, G. Molecular phenotype in mammary tumours of queens: Correlation between primary tumour and lymph node metastasis. J. Compar. Pathol. 2013, 148, 206-213
82. Martin de las Mulas, J.; Van Niel, M.; Millán, Y.; Ordás, J.; Blankenstein, M.A.; Van Mil, F.; Misdorp, W. Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Res. Vet. Sci. 2002, 72, 153-161
83. Millanta, F.; Calandrella, M.; Vannozzi, I.; Poli, A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet. Rec. 2006, 158, 821-824
84. Caliari, D.; Zappulli, V.; Rasotto, R.; Cardazzo, B.; Frassineti, F.; Goldschmidt, M.H.; Castagnaro, M. Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer. BMC Vet. Res. 2014, 10, 185
85. Carlson, R.W.; Allred, D.C.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Erban, J.K.; Farrar, W.B.; Goldstein, L.J.; Gradishar, W.J.; et al. Breast cancer. Clinical practice guidelines in oncology. J. Nat. Compr. Cancer Network 2009, 7, 122-192
86. Millanta, F.; Calandrella, M.; Citi, S.; Della Santa, D.; Poli, A. Overexpression of HER-2 in feline invasive mammary carcinomas: An immunohistochemical survey and evaluation of its prognostic potential. Vet. Pathol. 2005, 42, 30-34
87. Rasotto, R.; Caliari, D.; Castagnaro, M.; Zanetti, R.; Zappulli, V. An immunohistochemical study of HER-2 expression in feline mammary tumours. J. Compar. Pathol. 2011, 144, 170-179
88. Soares, M.; Correia, J.; Rodrigues, P.; Simões, M.; de Matos, A.; Ferreira, F. Feline HER2 protein expression levels and gene status in feline mammary carcinoma: Optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques. Microsc. Microanal. 2013, 19, 876-882
89. Winston, J.; Craft, D.M.; Scase, T.J.; Bergman, P.J. Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Vet. Compar. Oncol. 2005, 3, 8-15
90. Maniscalco, L.; Iussich, S.; de Las Mulas, J.M.; Millán, Y.; Biolatti B, Sasaki, N.; Nakagawa, T.; De Maria, R. Activation of AKT in feline mammary carcinoma: A new prognostic factor for feline mammary tumours. Vet. J. 2012, 191, 65-71
91. Gibson, H.M.; Veenstra, J.; Jones, R.F.; Vaishampayan, U.; Sauerbrey, M.; Bepler, G.; Lum, L.; Reyes, J.; Weise, A.; Wei, W.Z. Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunol. Res. 2015. doi:10.1158/2326-6066.CIR-14-0175. Available online: http://www.biomedcentral.com/1471-2407/13/218 (accessed on 25 June 2015)
92. Santos, S.; Baptista, C.S.; Abreu, R.M.; Bastos, E.; Amorim, I.; Gut, I.G.; Gärtner, F.; Chaves, R. ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer. PLoS ONE 2013, 8, doi:10.1371/journal.pone.0083673. Available online: http://journals.plos.org/plosone/article?id= 10.1371/journal.pone.0083673 (accessed on 25 June 2015)
93. Malhotra, G.K.; Zhao, X.; Band, H.; Band, V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol. Therapy 2010, 10, 955-960
94. Morrison, W.B. Inflammation and cancer: A comparative view. J. Vet. Intern. Med. 2012, 26, 18-31
95. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883-899
96. Vascellari, M.; Melchiotti, E.; Bozza, M.A.; Mutinelli, F. Fibrosarcomas at presumed sites of injection in dogs: Characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. J. Vet. Med. A Physiol. Pathol. Clin. Med. 2003, 50, 286-291
97. Vascellari, M.; Melchiotti, E.; Mutinelli, F. Fibrosarcoma with typical features of postinjection sarcoma at site of microchip implant in a dog: Histologic and immunohistochemical study. Vet. Pathol. 2006, 43, 545-548
98. Vascellari, M.; Mutinelli, F.; Cossettini, R.; Altinier, E. Liposarcoma at the site of an implanted microchip in a dog. Vet. J. 2004, 168, 188-190
99. Murray, J. Vaccine injection-site sarcoma in a ferret. J. Amer. Vet. Med. Assoc. 1998, 213, 955
100. Keel, S.B.; Jaffe, K.A.; Petur Nielsen, G.; Rosenberg, A.E. Orthopaedic implant-related sarcoma: A study of twelve cases. Modern Pathol. 2001, 14, 969-977
101. Liptak, J.M.; Forrest, L.J. Soft Tissue Sarcomas. In Withrow and MacEwen's Small Animal Clinical Oncology, 5th ed.; Withrow, S.J.; Vail, D.M.; Page, R.L., Eds.; Elsevier Saunders: St Louis, MO, USA, 2012; pp. 356-380
102. Dean, R.S.; Pfeiffer, D.U.; Adams, V.J. The incidence of feline injection site sarcomas in the United Kingdom. BMC Vet. Res. 2013, 9, 17
103. Doddy, F.D.; Glickman, L.T.; Glickman, N.W.; Janovitz, E.B. Feline fibrosarcomas at vaccination sites and non-vaccination sites. J. Compar. Pathol. 1996, 114, 165-174
104. Couto, S.S.; Griffey, S.M.; Duarte, P.C.; Madewell, B.R. Feline vaccine-associated fibrosarcoma: Morphologic distinctions. Vet. Pathol. 2002, 39, 33-41
105. Hendrick, M.J.; Brooks, J.J. Postvaccinal Sarcomas in the Cat: Histology and Immunohistochemistry. Vet. Pathol. 1994, 31, 126-129
106. Aberdein, D.; Munday, J.S.; Dyer, C.B.; Knight, C.G.; French, A.F.; Gibson, I.R. Comparison of the histology and immunohistochemistry of vaccination-site and non-vaccination-site sarcomas from cats in New Zealand. New Zealand Vet. J. 2007, 55, 203-207
107. Dubielzig, R.R.; Everitt, J.; Shadduck, J.A.; Albert, D.M. Clinical and morphologic features of post-traumatic ocular sarcomas in cats. Vet. Pathol. 1990, 27, 62-65
108. Douglas, J.L.; Gustin, J.K.; Moses, A.V.; Dezube, B.J.; Pantanowitz, L. Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation. Transl. Biomed. 2010, 1. Available online: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472629/ (accessed on 25 June 2015)
109. Jourdier, T.M.; Moste, C.; Bonnet, M.C.; Delisle, F.; Tafani, J.P.; Devauchelle, P.; Tartaglia, J.; Moingeon, P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Therapy 2003, 10, 2126-2132
110. Banerji, N.; Kanjilal, S. Somatic alterations of the p53 tumor suppressor gene in vaccine-associated feline sarcoma. Amer. J. Vet. Res. 2006, 67, 1766-1772
111. McEntee, M.C.; Page, R.L. Feline vaccine-associated sarcomas. J. Vet. Intern. Med. 2001, 15, 176-182
112. Tannehill-Gregg, S.; Kergosien, E.; Rosol, T.J. Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta. In Vitro Cell. Dev. Biol. Anim. 2001, 37, 676-683
113. Modiano, J.F.; Kokai, Y.; Weiner, D.B.; Pykett, M.J.; Nowell, P.C.; Lyttle, C.R. Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. J. Cell. Biochem. 1991, 45, 196-206
114. Norval, M.; Maingay, J.; Else, R.W. Characteristics of a feline mammary carcinoma cell line. Res. Vet. Sci. 1985, 39, 157-164
115. Uyama, R.; Hong, S.H.; Nakagawa, T.; Yazawa, M.; Kadosawa, T.; Mochizuki, M.; Tsujimoto, H.; Nishimura, R.; Sasaki, N. Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J. Vet. Med. Sci. 2005, 67, 1273-1276
116. Takauji, S.R.; Watanabe, M.; Uyama, R.; Nakagawa, T.; Miyajima, N.; Mochizuki, M.; Nishimura, R.; Sugano, S.; Sasaki, N. Expression and subcellular localization of E-cadherin, alpha-catenin, and beta-catenin in 8 feline mammary tumor cell lines. J. Vet. Med. Sci. 2007, 69, 831-834
117. Muleya, J.S.; Nakaichi, M.; Sugahara, J.; Taura, Y.; Murata, T.; Nakama, S. Establishment and characterization of a new cell line derived from feline mammary tumor. J. Vet. Med. Sci. 1998, 60, 931-935
118. Muleya, J.S.; Nakaichi, M.; Taura, Y.; Yamaguchi, R.; Nakama, S. In-vitro anti-proliferative effects of some anti-tumour drugs on feline mammary tumour cell lines. Res. Vet. Sci. 1999, 66, 169-174
119. Minke, J.M.; Schuuring, E.; van den Berghe, R.; Stolwijk, J.A.; Boonstra, J.; Cornelisse, C.; Hilkens, J.; Misdorp, W. Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors. Cancer Res. 1991, 51, 4028-4037
120. Adelfinger, M.; Gentschev, I.; Grimm de Guibert, J.; Weibel, S.; Langbein-Laugwitz, J.; Härtl, B.; Murua Escobar, H.; Chen, N.G.; Aguilar, R.J.; Yu, Y.A.; et al. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy. PLoS ONE 2014, 9, doi:10.1371/journal.pone.0104337. Available online: http://journals.plos.org/plosone/ article?id=10.1371/journal.pone.0104337 (accessed on 25 June 2015)
121. Williams, L.E.; Banerji, N.; Klausner, J.S.; Kapur, V.; Kanjilal, S. Establishment of two vaccineassociated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone. Amer. J. Vet. Res. 2001, 62, 1354-1357
122. Banerji, N.; Li, X.; Klausner, J.S.; Kapur, V.; Kanjilal, S. Evaluation of in vitro chemosensitivity of vaccine-associated feline sarcoma cell lines to vincristine and paclitaxel. Amer. J. Vet. Res. 2002, 63, 728-732
123. Katayama, R.; Huelsmeyer, M.K.; Marr, A.K.; Kurzman, I.D.; Thamm, D.H.; Vail, D.M. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother. Pharmacol. 2004, 54, 25-33
124. Lawrence, J.; Saba, C.; Gogal, R., Jr.; Lamberth, O.; Vandenplas, M.L.; Hurley, D.J.; Dubreuil, P.; Dobbin, K.; Turek., M. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Vet. Compar. Oncol. 2012, 10, 143-154